

PATENT  
Attorney Reference Number 6613-66749

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: David Jonathan Madge et al.

CERTIFICATE OF MAILING

Application No. 10/658,971

Filed: September 9, 2003

Confirmation No. 3998

For: BORONIC ACID SALTS USEFUL IN  
PARENTERAL FORMULATIONS

Examiner: To be assigned

Art Unit: 1615

Attorney Reference No. 6613-66749

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)

*Wayne W. Rupert*

Date Mailed February 20, 2004

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form PTO-1449 and references cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

*Wayne W. Rupert*

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** David Jonathan Madge et al.**Application No.** 10/658,971**Filed:** September 9, 2003**Confirmation No.** 3998**For:** BORONIC ACID SALTS USEFUL IN  
PARENTERAL FORMULATIONS**Examiner:** To be assigned**Art Unit:** 1615**Attorney Reference No.** 6613-66749CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)Date Mailed February 20, 2004**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Wayne W. Rupert  
Registration No. 34,420

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<b>Attorney Docket Number</b>	6613-66749
<b>Application Number</b>	10/658,971
<b>Filing Date</b>	September 9, 2003
<b>First Named Inventor</b>	David Jonathan Madge
<b>Art Unit</b>	1615
<b>Examiner Name</b>	To be assigned

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		4,499,082	12 Feb 1985	Shenvi et al.
		4,701,545	20 Oct 1987	Matteson et al.
		4,935,493	19 Jun 1990	Bachovchin et al.
		4,963,655	16 Oct 1990	Kinder et al.
		5,187,157	16 Feb 1993	Kettner et al.
		5,444,049	22 Aug 1995	de Nanteuil et al.
		5,462,964	31 Oct 1995	Fevig et al.
		5,563,127	08 Oct 1996	Amparo et al.
		5,574,014	12 Nov 1996	Claeson et al.
		5,585,360	17 Dec 1996	de Nanteuil et al.
		5,658,885	19 Aug 1997	Lee et al.
		5,681,978	28 Oct 1997	Matteson et al.
		5,731,439	24 Mar 1998	Carini et al.
		5,780,454	14 Jul 1998	Adams et al.
		5,814,622	29 Sep 1998	de Nanteuil et al.
		6,066,730	23 May 2000	Adams et al.
		6,313,096	06 Nov 2001	Claeson et al.

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Attorney Docket Number</b>	6613-66749
				<b>Application Number</b>	10/658,971
				<b>Filing Date</b>	September 9, 2003
				<b>First Named Inventor</b>	David Jonathan Madge
				<b>Art Unit</b>	1615
				<b>Examiner Name</b>	To be assigned
		6,465,433	15 Oct 2002	Adams et al.	
<b>FOREIGN PATENT DOCUMENTS</b>					
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Number</b>	<b>Date</b>	<b>Country</b>	
		0471651	19 Feb 1992	EPC	
		WO 92/07869	14 May 1992	WIPO/PCT	
		WO 94/21650	29 Sep 1994	WIPO/PCT	
		WO 94/25049	10 Nov 1994	WIPO/PCT	
		WO 95/09634	13 Apr 1995	WIPO/PCT	
		WO 95/09858	13 Apr 1995	WIPO/PCT	
		WO 95/09859	13 Apr 1995	WIPO/PCT	
		WO 96/13266	09 May 1996	WIPO/PCT	
		WO 96/20689	11 Jul 1996	WIPO/PCT	
		WO 97/05161	13 Feb 1997	WIPO/PCT	
		WO 98/31688	23 Jul 1998	WIPO/PCT	
		WO 99/26652	03 Jun 1999	WIPO/PCT	
		WO 00/35904	22 Jun 2000	WIPO/PCT	
		WO 00/35905	22 Jun 2000	WIPO/PCT	
		WO 00/41715	20 Jul 2000	WIPO/PCT	
		WO 01/41796	14 Jun 2001	WIPO/PCT	

<b>EXAMINER SIGNATURE:</b>	<b>DATE CONSIDERED:</b>
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Attorney Docket Number</b>		6613-66749
				<b>Application Number</b>		10/658,971
				<b>Filing Date</b>		September 9, 2003
				<b>First Named Inventor</b>		David Jonathan Madge
				<b>Art Unit</b>		1615
				<b>Examiner Name</b>		To be assigned
		WO 01/02424	11 Jan 2001	WIPO/PCT		
		WO 02/36157	10 May 2002	PCT		
		WO 02/059130	01 Aug 2002	WIPO/PCT		
		WO 02/059131	01 Aug 2002	WIPO/PCT		
		WO 03/007984	30 Jan 2003	WIPO/PCT		
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>				
		Claeson et al., <i>Thromb Haemostas</i> , Vol. 65, p. 1289, 1991.				
		Claeson et al., "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in <i>Peptides, Chemistry and Biology</i> , Smith J A, Rivier J E, Eds., <i>Escom: Leiden</i> pp. 824-825, 1992.				
		Claeson et al., <i>Biochem J.</i> 290:309-312, 1993.				
		Claeson et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:83-89, 1993.				
		Claeson, <i>Blood Coagulation and Fibrinolysis</i> 5:411-436, 1994.				
		Coburn, <i>Exp. Opin. Ther. Patents</i> 11(5):721-738, 2001.				
		Contreras et al., <i>J. Org. Chem.</i> 246:213-217, 1983.				
		Deadman et al., <i>J. Medicinal Chemistry</i> 38:1511-1522, 1995.				
		Deadman et al., <i>J. Enzyme Inhibition</i> 9:29-41, 1995.				
		Elgendy et al., <i>Thromb Haemostas</i> 65:775, 1991.				
		Elgendy et al., <i>Tetrahedron Letters</i> 33(29):4209-4212, 1992.				
		Elgendy et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:173-178, 1993.				
		Elgendy et al., <i>Tetrahedron</i> 50(12):3803-3812, 1994.				
<b>EXAMINER SIGNATURE:</b>				<b>DATE CONSIDERED:</b>		
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.						

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	6613-66749
		<b>Application Number</b>	10/658,971
		<b>Filing Date</b>	September 9, 2003
		<b>First Named Inventor</b>	David Jonathan Madge
		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	To be assigned
		Esmail et al., <i>Thrombosis and Haemostasis</i> 6:1318, 1995.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:91-92, 1997.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:498-499, 1997.	
		Gerrard et al., <i>Thrombosis and Haemostasis</i> 6:1307, 1995.	
		Gustafsson et al., <i>Thrombosis Research</i> 101:171-181, 2001.	
		Katz et al., <i>Biochemistry</i> 34(26):8264-8280, 1995.	
		Martichonok et al., <i>J. Am. Chem. Soc.</i> 118:950-958, 1996.	
		Matt et al., <i>Bioorg. Med. Chem.</i> 8:2291-2303, 2000.	
		Matteson, <i>Chem. Rev.</i> 89:1535-1551, 1989.	
		Matteson et al., <i>J. Org. Chem.</i> 61:6047-6051, 1996.	
		Metternich et al., <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> 97:345, 1992.	
		Philipp et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:67-77, 1993.	
		Rewinkel et al., <i>Current Pharmaceutical Design</i> 5:1043-1075, 1999.	
		Saitoh et al., <i>Pharmaceutical Research</i> 16(11):1786-1789, 1999.	
		Sanderson et al., <i>Current Medicinal Chemistry</i> 5:289-304, 1998.	
		Skordalakes et al., <i>Biochemistry</i> 37(41):14420-14427, 1998.	
		Spencer et al., <i>Tetrahedron</i> 58:1551-1556, 2002.	
		Stahl et al., <i>Handbook of Pharmaceutical Salts Properties, Selection, and Use</i> , Verlag Helvetica Chimica Acta, Postfach, CH-8042 Zürich, Switzerland, 2002.	
		Tapparelli et al., <i>The Journal of Biological Chemistry</i> 268(7):4734-4741, 1993.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

[illegible]

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	